CareRx Corporation Receives Regulatory Approval for Renewal of its Normal Course Issuer Bid

In This Article:

TORONTO, Sept. 3, 2024 /CNW/ - CareRx Corporation ("CareRx" or "the Company") (TSX: CRRX) today announced that the Toronto Stock Exchange (the "TSX") has approved the Company's normal course issuer bid (the "NCIB") to purchase for cancellation up to 1,500,000 of its common shares ("Shares"), representing approximately 2.5% of its 60,075,433 issued and outstanding Shares as at August 27, 2024.

It is expected that the NCIB will begin on September 7, 2024 and will end on September 6, 2025. Daily purchases on the TSX under the NCIB will be limited to 3,521 Shares, other than purchases made pursuant to the block purchase exception, being 25% of the average daily trading volume on the TSX for the six months ending July 31, 2024. The actual number of Shares to be purchased, and the timing of any such purchases, will be determined by the Company, subject to the applicable rules and policies of the TSX. All Shares acquired will be cancelled.

The Company previously maintained a normal course issuer bid for the twelve-month period commencing on September 6, 2023 and ending on September 7, 2024 (the "Previous NCIB"), under which the Company sought and received approval from the TSX to purchase up to 1,000,000 Shares. As of August 27, 2024, the Company has purchased 256,148 Shares under the Previous NCIB at a weighted average purchase price of $2.13 per Share through the facilities of the TSX and alternative Canadian trading systems.

Although the Company presently intends to purchase Shares under its NCIB, there can be no assurances that any such purchases will be completed. The purchases will be made through the facilities of the TSX and/or any alternative trading system in Canada. The Company will pay the market price for the common shares at the time of acquisition and the purchases will be made in accordance with applicable regulatory requirements.

About CareRx Corporation

CareRx is Canada's leading provider of pharmacy services to seniors living communities. We serve approximately 90,000 residents in approximately 1,450 seniors and other congregate care communities (long-term care homes, retirement homes, assisted living facilities, and group homes). We are a national organization with a large network of pharmacy fulfillment centres strategically located across the country. This allows us to deliver medications in a timely and cost-effective manner and quickly respond to routine changes in medication management. We use best-in-class technology that automates the preparation and verification of multi-dose compliance packaging of medication, providing the highest levels of safety and adherence for individuals with complex medication regimens. We take an active role in working with our home operator partners to promote resident health, staff education, and medication system quality and efficiency.